The Efficacy of Topical Cetirizine for Patients with Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Almahzoum Kholoud K, Aladwani Manar M MM, Alhenaidi Maryam W MW, Alrumaih Omar W OW et al.
Topical cetirizine has been proposed as a potential treatment for androgenetic alopecia (AGA) because of its anti-inflammatory effects and its ability to modulate prostaglandin pathways implicated in follicular miniaturization. However, the available clinical evidence remains limited. This study evaluated the efficacy and safety of topical cetirizine in androgenic alopecia (AGA). We searched PubMed, Embase, Scopus, Web of Science, and the Cochrane Library from inception to 29 March 2026 for clinical studies evaluating topical cetirizine in male AGA or female pattern hair loss. Comparative studies with extractable continuous data were included in quantitative synthesis, while the remaining studies were synthesized narratively. Random-effects meta-analysis was performed using mean differences (MD) with 95% confidence intervals (CI). Eight studies were included, of which four contributed data to at least one pooled meta-analysis. Comparator-stratified analyses showed that favorable effects were mainly confined to placebo/vehicle-controlled evidence, whereas studies using active minoxidil comparators or add-on-to-minoxidil designs did not demonstrate a clear advantage for cetirizine. The exploratory overall pooled estimates were not statistically significant for total hair density or terminal hair density. A significant effect was observed for vellus hair density, but this finding was driven almost entirely by one non-randomized study with unusually small SDs and was not robust on sensitivity analysis. Narrative findings suggested possible improvements in dermoscopic regrowth, photographic response, patient-reported outcomes, and hair shaft thickness. Adverse events were infrequently reported and no major safety signal emerged. Topical cetirizine may have biologic and clinical activity in AGA, but current evidence remains limited, heterogeneous, and of low certainty. Comparator-stratified analyses do not support a consistent advantage over active minoxidil comparators or add-on-to-minoxidil regimens. It should be regarded as a promising but unproven option requiring larger, standardized randomized trials.